Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 16:35:05 22/05/2024 BST			5-day change	1st Jan Change
41 ^GBX	-1.80%		-7.34%	-64.81%

05-07	AstraZeneca target raised; Antofagasta lowered	AN
05-01	Avacta picks Christina Coughlin to replace long-serving CEO	AN

Mike Owen Steps Down from Avacta Group plc as Non-Executive Director, with Effect from 24 March 2021

March 25, 2021 at 03:02 pm

Avacta Group plc announced that the Dr. Mike Owen has stepped down from his role as Non-executive Director of the Avacta Group plc Board, a position which he has held since 2015, with effect from 24 March 2021.

Latest news about Avacta Group Plc

AstraZeneca target raised; Antofagasta lowered	05-07	AN
Avacta picks Christina Coughlin to replace long-serving CEO	05-01	AN
EARNINGS: Avacta sales jump; Poolbeg loss narrows; Digital 9 NAV down	04-30	AN
Avacta Group CEO Steps Down; Successor Appointed	04-30	MT
Transcript : Avacta Group Plc, 2023 Earnings Call, Apr 30, 2024	04-30
Avacta Group Plc Reports Earnings Results for the Full Year Ended December 31, 2023	04-30	CI
Avacta Group plc Announces Chief Executive Officer Changes	04-30	CI
First Tin updates Tellerhauser estimates	04-22	AN
Transcript : Avacta Group Plc - Special Call	04-10
Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting	04-09	CI
Avacta doses third patient in drug conjugate trial for tumour tissue	03-21	AN
Avacta shareholders give AGM go-ahead to issue new shares	03-18	AN
EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract	03-05	AN
Avacta Group Upsizes Share Placement Amid Strong Investor Demand	02-29	MT
Avacta increases placing size to GBP26 million thanks to strong demand	02-29	AN
AIM WINNERS & LOSERS: Beacon Energy and Avacta fall on fundraise	02-29	AN
Avacta plans fundraise to fund clinical development	02-28	AN
Avacta says new head of R&D Coughlin brings "deep expertise"	01-19	AN
Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer	01-19	CI
Avacta taps biopharma veteran as Therapeutics business chief	12-19	AN
Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division	12-19	CI
Avacta says study shows cancer treatment AVA6000 working as planned	12-13	AN
Transcript : Avacta Group Plc - Special Call	12-13
Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study	12-13	CI
Avacta loss widens on cost rise but clinical tests positive	28/09/23	AN

Chart Avacta Group Plc

Duration

Period

More charts

Company Profile

Avacta Group plc is a United Kingdom-based life sciences company focused on improving healthcare outcomes through targeted cancer treatments and diagnostics. The Company has two segments: Therapeutics and Diagnostics. The Therapeutics segment is a clinical stage oncology biotech division harnessing therapeutic platforms to develop novel, highly targeted cancer drugs. The Diagnostics segment is focused on supporting healthcare professionals and broadening access to diagnostics. It has two platforms: preICISION and Affimer. The Company's preICISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preICISION platform harnesses this tumor specific protease to activate preICISION peptide drug conjugates and preICISION antibody/Affimer drug conjugates in the tumor microenvironment. Its lead preICISION program AVA6000, a peptide drug conjugate form of doxorubicin, is in Phase 1 studies.

Sector

Biotechnology & Medical Research

Calendar

25/09/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Avacta Group Plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.41 GBP

Average target price

0.8233 GBP

Spread / Average Target

+100.81%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AVACTA GROUP PLC	-64.81%	189M
VERTEX PHARMACEUTICALS INCORPORATED	+9.99%	114B
REGENERON PHARMACEUTICALS, INC.	+12.01%	107B
BIONTECH SE	-3.07%	22.22B
ARGENX SE	-0.67%	21.28B
GENMAB A/S	-4.64%	18.8B
BEIGENE, LTD.	-6.90%	17.51B
WUXI APPTEC CO., LTD.	-39.36%	17.17B
NEUROCRINE BIOSCIENCES, INC.	+5.82%	14.14B
SAREPTA THERAPEUTICS, INC.	+33.05%	12.2B

Bio Therapeutic Drugs